ArticleNPJ breast cancer2025

Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab.

Giorgio Bonomi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.